Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Books $9 Million Milestone from Merck Serono

publication date: Sep 16, 2014
BeiGene, a Beijing novel drug developer, received a $9 million milestone from Merck Serono for starting a Phase I trial of BGB-290, a second generation PARP inhibitor. Less than a year ago, Merck Serono and BeiGene entered a co-development agreement for BGB-290 in a deal than included an unspecified upfront payment and $232 million of milestones. It was the second transaction between the two companies and the second to trigger a milestone. In May, BeiGene received a $5 million milestone from Merck Serono for starting a clinical trial of BGB-283, a second-generation BRAF inhibitor. More details....

Stock Symbol: (XETRA: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital